Matthew Buten - 07 Jan 2022 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role
Chief Financial Officer
Signature
/s/ George Clark, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
07 Jan 2022
Net transactions value
$0
Form type
4
Filing time
07 Jan 2022, 20:19:03 UTC
Previous filing
04 Jan 2022
Next filing
28 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Employee Stock Option (Right to Buy) Award $0 +26,000 $0.000000 26,000 07 Jan 2022 Common Shares 26,000 $128.87 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date.